GO:0048514 blood vessel morphogenesis: Angiogenesis Pathway, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0048514 blood vessel morphogenesis describes the biological process by which the anatomical structures of blood vessels are generated and organized.
• It encompasses sprouting angiogenesis, intussusceptive angiogenesis, and other modes of vessel formation that build the vascular network.
• Endothelial cell behavior during blood vessel morphogenesis is controlled by VEGF, Notch, angiopoietin, and TGF-beta signaling, among other pathways.
• Non-collagenous extracellular matrix proteins provide instructive cues that guide vessel morphogenesis in development and cancer.
• Blood vessel morphogenesis is coupled to osteogenesis in bone through specialized vessel subtypes and endothelial Notch activity.
• Dysregulated blood vessel morphogenesis contributes to tumor progression, metastasis, and other angiogenesis-dependent diseases.
Description
Blood vessel morphogenesis (GO:0048514) is the developmental and homeostatic process that generates and organizes the anatomical structures of blood vessels, the vasculature that carries blood throughout the body. This process is fundamental to embryonic development, organ growth, tissue repair, and the pathogenesis of numerous diseases, because every cell in a multicellular organism depends on a functional vascular supply for oxygen and nutrients. Researchers study blood vessel morphogenesis to understand how endothelial cells coordinate to form patent, hierarchically branched, and functionally specialized vessels, and to identify therapeutic targets for conditions driven by abnormal angiogenesis. The term covers multiple modes of vessel formation, including sprouting angiogenesis, intussusceptive angiogenesis, and other recently recognized mechanisms that together build and remodel the vascular tree. At the cellular level, blood vessel morphogenesis requires precise control of endothelial cell proliferation, migration, polarity, lumen formation, and interaction with mural cells and the extracellular matrix. In bone, blood vessel morphogenesis is tightly coupled to osteogenesis through specific vessel subtypes and endothelial Notch signaling, illustrating how vascular morphogenesis is integrated with organ-specific development. Because dysregulated blood vessel morphogenesis underlies tumor growth, metastasis, and many ischemic and inflammatory disorders, it remains a central topic in vascular biology, cancer research, and regenerative medicine.
blood vessel morphogenesis At A Glance
| GO ID | GO:0048514 |
|---|---|
| GO term | blood vessel morphogenesis |
| Ontology | biological_process |
| Synonym | None |
| Major function | Generation and organization of the anatomical structures of blood vessels |
| Related processes | Angiogenesis, vasculogenesis, tubulogenesis, vessel remodeling |
| Cellular players | Endothelial cells, mural cells, pericytes, smooth muscle cells |
| Key signaling pathways | VEGF, Notch, Angiopoietin, TGF-beta, ECM-integrin signaling |
| Physiological contexts | Embryonic development, organ growth, bone formation, wound healing |
| Pathological contexts | Tumor angiogenesis, metastasis, ischemic disease, vascular malformations |
What Is GO:0048514?
According to the Gene Ontology, GO:0048514 blood vessel morphogenesis is defined as the process in which the anatomical structures of blood vessels are generated and organized, where the blood vessel is the vasculature carrying blood. In other words, it is the biological process that builds the physical architecture of blood vessels, including their formation, shaping, branching, and remodeling into a functional vascular network.
Why Is blood vessel morphogenesis Important in Cell Biology?
Blood vessel morphogenesis is essential for normal development and tissue homeostasis because it establishes the vascular network that delivers oxygen and nutrients and removes metabolic waste. Defects in this process cause embryonic lethality, vascular malformations, and impaired organ function, while excessive or aberrant blood vessel morphogenesis contributes to tumor growth, metastasis, and inflammatory diseases. Understanding the molecular and cellular control of blood vessel morphogenesis therefore has broad implications for developmental biology, cancer therapy, and regenerative medicine.
• Required for embryonic development and organogenesis, as vessels must form to support growing tissues.
• Controls tumor angiogenesis and metastasis, making it a major target in cancer research.
• Coupled to osteogenesis in bone through specialized vessel subtypes and Notch signaling.
• Involves multiple modes of angiogenesis, including sprouting and intussusceptive mechanisms.
• Dependent on non-collagenous ECM proteins that guide endothelial cell behavior.
• Regulated by endothelial cell-intrinsic signaling pathways such as VEGF and Notch.
• Dysregulation leads to vascular malformations, ischemic disease, and chronic inflammation.
• Provides a paradigm for studying tubulogenesis and lumen formation in other organs.
• Offers therapeutic opportunities for anti-angiogenic and pro-angiogenic strategies.
• Integrates with metabolic and immune signals, including macrophage metabolism.
What Happens During blood vessel morphogenesis?
Initiation and sprouting
In simple terms: Endothelial cells receive signals to start forming new vessel sprouts.
Blood vessel morphogenesis begins when endothelial cells respond to pro-angiogenic cues such as VEGF, leading to the selection of tip cells that extend filopodia and guide new sprouts. This sprouting process is a primary mode of angiogenesis and is tightly regulated by Notch signaling, which coordinates tip and stalk cell identities. The initiation of sprouting requires breakdown of the basement membrane and interaction with the extracellular matrix, including non-collagenous ECM proteins that modulate endothelial cell behavior.
Migration, proliferation, and guidance
In simple terms: Endothelial cells move and multiply to extend the new vessel in the right direction.
Once a sprout is initiated, endothelial cells migrate and proliferate to elongate the vessel, following guidance cues from the extracellular matrix and neighboring cells. This phase depends on dynamic regulation of cell adhesion, cytoskeletal remodeling, and polarity, and is influenced by ECM composition and stiffness. Notch signaling maintains a balance between tip and stalk cells, ensuring proper sprout extension and branching.
Lumen formation and tubulogenesis
In simple terms: The solid endothelial cord hollows out to create a tube that can carry blood.
Lumen formation is a critical step in blood vessel morphogenesis, converting endothelial cords into patent tubes. This process shares mechanisms with tubulogenesis in other organs and involves coordinated cell shape changes, cell rearrangement, and establishment of apical-basal polarity. Proper lumen formation is essential for vessel function and is regulated by interactions with the ECM and surrounding cells.
Vessel fusion, remodeling, and maturation
In simple terms: New vessel segments connect, prune, and stabilize to form a mature network.
After lumen formation, vessel segments fuse and remodel into a hierarchical network through processes such as intussusceptive angiogenesis and pruning. Maturation involves recruitment of mural cells (pericytes and smooth muscle cells) and deposition of a stable basement membrane, which stabilizes the vessel and regulates permeability. In bone, endothelial Notch activity promotes angiogenesis and osteogenesis, illustrating how vessel maturation is coupled to organ-specific functions.
Metabolic and immune regulation
In simple terms: Immune cells and their metabolism can influence how blood vessels form.
Macrophage metabolism controls tumor blood vessel morphogenesis and metastasis, highlighting the role of immune-metabolic crosstalk in vessel formation. This regulation involves changes in macrophage polarization and metabolic pathways that affect the angiogenic microenvironment. Such interactions are important in cancer and other diseases where inflammation and angiogenesis are linked.
Key Genes Involved in GO:0048514 blood vessel morphogenesis
The following genes and proteins are central to blood vessel morphogenesis, based on published literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| VEGFA | Key pro-angiogenic growth factor | Target for anti-angiogenic therapy and vessel growth studies |
| KDR (VEGFR2) | Primary VEGF receptor on endothelial cells | Mediates sprouting and proliferation signals |
| FLT1 (VEGFR1) | Modulates VEGF signaling | Regulates tip cell selection and vessel patterning |
| DLL4 | Notch ligand in endothelial cells | Controls tip/stalk cell specification and branching |
| NOTCH1 | Notch receptor | Regulates endothelial cell fate and vessel maturation |
| ANGPT1 | Angiopoietin ligand | Promotes vessel stabilization and mural cell recruitment |
| ANGPT2 | Angiopoietin ligand | Destabilizes vessels and promotes sprouting |
| TEK (TIE2) | Angiopoietin receptor | Regulates vessel quiescence and stability |
| PECAM1 (CD31) | Endothelial cell adhesion molecule | Marker of endothelial cells and regulator of junctional integrity |
| CDH5 (VE-cadherin) | Endothelial adherens junction protein | Controls vascular permeability and lumen formation |
| FN1 (Fibronectin) | Non-collagenous ECM protein | Guides endothelial migration and morphogenesis |
| SPARC | Matricellular protein | Modulates angiogenesis and vessel maturation |
| TGFB1 | Growth factor | Regulates endothelial and mural cell behavior |
| PDGFB | Growth factor | Recruits pericytes and smooth muscle cells |
| HIF1A | Hypoxia-inducible factor | Drives VEGF expression under hypoxia |
| MMP2 | Matrix metalloproteinase | Degrades ECM to permit sprouting |
| MMP9 | Matrix metalloproteinase | Remodels ECM during angiogenesis |
How Is blood vessel morphogenesis Regulated?
Blood vessel morphogenesis is regulated by a complex interplay of growth factor signaling, cell-cell communication, and extracellular matrix interactions. VEGF signaling through VEGFR2 is a primary driver of endothelial cell proliferation and migration, while Notch signaling via DLL4 and NOTCH1 coordinates tip and stalk cell identities to ensure proper sprouting. Angiopoietins (ANGPT1, ANGPT2) and their receptor TIE2 regulate vessel stabilization and quiescence. In bone, endothelial Notch activity promotes angiogenesis and osteogenesis, linking vessel morphogenesis to bone development. Macrophage metabolism also controls tumor blood vessel morphogenesis, indicating that immune-metabolic pathways regulate vessel formation in the tumor microenvironment. Non-collagenous ECM proteins such as fibronectin and SPARC provide additional regulatory cues that modulate endothelial cell behavior during morphogenesis.
blood vessel morphogenesis and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| VEGFA | Tumor angiogenesis, metastasis | Xenograft models with VEGF overexpression or knockout |
| DLL4 | Vascular malformations, tumor vessel abnormalities | Endothelial-specific knockout or point mutation |
| NOTCH1 | Bone development, skeletal disorders | Conditional knockout in bone endothelial cells |
| ANGPT2 | Inflammation, vascular leakage | Knockout or overexpression in mouse models |
| HIF1A | Ischemic disease, tumor hypoxia | Hypoxia-inducible knockout or knock-in |
Cancer and metastasis
Tumor blood vessel morphogenesis is often aberrant, producing leaky, tortuous vessels that support tumor growth and metastasis. Macrophage metabolism controls tumor blood vessel morphogenesis and metastasis, highlighting the role of the tumor microenvironment in regulating angiogenesis. Non-collagenous ECM proteins in the tumor stroma also influence vessel morphogenesis and cancer progression. Anti-angiogenic therapies targeting VEGF and Notch pathways aim to normalize tumor vasculature and inhibit metastasis.
Bone development and skeletal disorders
Blood vessel morphogenesis is coupled to osteogenesis through specialized vessel subtypes and endothelial Notch activity. Disruption of this coupling can lead to skeletal defects and impaired bone regeneration. Understanding the molecular links between angiogenesis and osteogenesis may inform treatments for bone diseases.
Ischemic and vascular diseases
Insufficient blood vessel morphogenesis contributes to ischemic diseases such as myocardial infarction and stroke, where inadequate collateral vessel formation limits tissue perfusion. Conversely, excessive or abnormal vessel morphogenesis is implicated in vascular malformations and retinopathies. Therapeutic strategies aim to promote or inhibit vessel morphogenesis depending on the disease context.
Inflammatory and metabolic disorders
Chronic inflammation and metabolic dysregulation can alter blood vessel morphogenesis, contributing to diseases such as atherosclerosis and diabetic complications. Macrophage metabolism is a key link between inflammation and vessel morphogenesis in tumors and possibly other tissues. ECM remodeling also plays a role in inflammation-associated angiogenesis.
From blood vessel morphogenesis-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Is a gene required for endothelial sprouting? | Endothelial-specific knockout (e.g., Cdh5-Cre) |
| Does a point mutation alter VEGFR2 signaling? | Knock-in of point mutation in Kdr |
| How does a gene affect vessel maturation? | Tagged knock-in for lineage tracing or imaging |
| Can overexpression of a factor promote angiogenesis? | Endothelial-specific overexpression |
| What is the role of a gene in tumor vessel morphogenesis? | Tumor xenograft with gene knockout or overexpression |
| How does a gene regulate bone angiogenesis? | Bone-specific knockout or knock-in |
How to Study the blood vessel morphogenesis Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Aortic ring assay | Endothelial sprouting | Screening pro- and anti-angiogenic factors |
| Retinal angiogenesis model | Vessel sprouting and branching in vivo | Studying developmental angiogenesis |
| Tumor xenograft | Tumor vessel morphogenesis and metastasis | Evaluating anti-angiogenic therapies |
| Bone angiogenesis model | Coupling of angiogenesis and osteogenesis | Bone development studies |
| Confocal microscopy | Vessel density, lumen formation | Quantifying morphogenetic changes |
| RNA sequencing | Transcriptional changes in endothelial cells | Identifying regulators of morphogenesis |
| Proteomics | Protein expression and modifications | Discovering signaling networks |
| Single-cell RNA-seq | Endothelial cell heterogeneity | Mapping tip/stalk cell populations |
Endothelial cell sprouting assays
In vitro sprouting assays, such as the aortic ring assay or spheroid sprouting assay, are used to measure the ability of endothelial cells to form sprouts in response to angiogenic stimuli. These assays help identify genes and pathways that regulate blood vessel morphogenesis.
In vivo vascular morphogenesis models
Mouse models including retinal angiogenesis, tumor xenografts, and bone angiogenesis models allow the study of blood vessel morphogenesis in a physiological context. These models can be combined with genetic manipulation to test gene function.
Imaging and quantification
Confocal and multiphoton microscopy of endothelial markers (e.g., PECAM1, CDH5) enable visualization and quantification of vessel density, branching, and lumen formation. Intravital imaging can track dynamic vessel morphogenesis in live animals.
Molecular and omics approaches
RNA sequencing, proteomics, and single-cell transcriptomics of endothelial cells during morphogenesis reveal gene expression changes and signaling networks. Bioinformatics analysis of public datasets can identify novel regulators of blood vessel morphogenesis.
How CRISPR Can Be Used to Study GO:0048514 blood vessel morphogenesis
Knockout
CRISPR knockout of genes such as VEGFA, DLL4, or NOTCH1 in endothelial cells or mouse models can reveal their essential roles in blood vessel morphogenesis. Knockout studies help determine whether a gene is required for sprouting, lumen formation, or vessel maturation.
Point Mutation
CRISPR point mutation can be used to model specific amino acid changes in receptors like VEGFR2 or NOTCH1 to dissect signaling mechanisms without completely abolishing protein function. Such models are valuable for understanding how disease-associated mutations affect blood vessel morphogenesis.
Knock-in
Knock-in of reporter genes (e.g., GFP) or tags into endogenous loci such as CDH5 or PECAM1 allows visualization and tracking of endothelial cells during blood vessel morphogenesis. Knock-in of human disease variants can also model vascular disorders.
Overexpression
CRISPR-mediated overexpression of pro-angiogenic factors like VEGFA or ANGPT1 can promote blood vessel morphogenesis in models of ischemia or tissue regeneration. Overexpression studies help identify sufficiency of a gene to drive vessel formation.
How EDITGENE Supports blood vessel morphogenesis Research
Researchers studying blood vessel morphogenesis-related genes often need to determine whether a candidate gene is causally involved in endothelial cell behavior, vessel patterning, or disease progression. EDITGENE provides comprehensive CRISPR-based services to generate precisely engineered cell and animal models for such studies.
Contact EDITGENE today to design your custom CRISPR model for blood vessel morphogenesis research.
Frequently Asked Questions About blood vessel morphogenesis
What is blood vessel morphogenesis?
Blood vessel morphogenesis (GO:0048514) is the biological process in which the anatomical structures of blood vessels are generated and organized, forming the vasculature that carries blood.
What genes are involved in blood vessel morphogenesis?
Key genes include VEGFA, KDR, DLL4, NOTCH1, ANGPT1, ANGPT2, TEK, PECAM1, CDH5, and ECM proteins such as FN1 and SPARC.
What are the main stages of blood vessel morphogenesis?
Main stages include sprouting initiation, endothelial cell migration and proliferation, lumen formation, vessel fusion, remodeling, and maturation.
How is blood vessel morphogenesis regulated?
It is regulated by VEGF, Notch, angiopoietin, TGF-beta signaling, ECM interactions, and metabolic cues from immune cells.
What diseases are associated with abnormal blood vessel morphogenesis?
Cancer, metastasis, bone disorders, ischemic diseases, vascular malformations, and inflammatory conditions.
What is the role of Notch signaling in blood vessel morphogenesis?
Notch signaling via DLL4 and NOTCH1 coordinates tip and stalk cell identities and promotes vessel maturation and osteogenesis.
How do macrophages influence blood vessel morphogenesis?
Macrophage metabolism controls tumor blood vessel morphogenesis and metastasis, linking immune-metabolic pathways to angiogenesis.
What methods are used to study blood vessel morphogenesis?
Methods include aortic ring assays, retinal angiogenesis models, tumor xenografts, confocal imaging, RNA-seq, and proteomics.
What is the difference between angiogenesis and blood vessel morphogenesis?
Angiogenesis is one mode of blood vessel morphogenesis; blood vessel morphogenesis also includes vasculogenesis, intussusceptive angiogenesis, and vessel remodeling.
How can CRISPR be used to study blood vessel morphogenesis?
CRISPR knockout, point mutation, knock-in, and overexpression enable functional studies of genes in endothelial cells and animal models.
Conclusion
Blood vessel morphogenesis (GO:0048514) is a fundamental biological process that builds and organizes the vascular network, with critical roles in development, bone formation, cancer, and ischemic disease. Understanding its molecular regulation by VEGF, Notch, angiopoietin, and ECM cues provides opportunities for therapeutic intervention. CRISPR-based models and advanced imaging and omics methods continue to uncover new regulators of this process, driving progress in vascular biology and medicine.
References
- 1. Wenes M et al.. 2016. Macrophage Metabolism Controls Tumor Blood Vessel Morphogenesis and Metastasis.. Cell Metab 24(5):701-715 PMID: 27773694
- 2. Dudley AC et al.. 2023. The modes of angiogenesis: an updated perspective.. Angiogenesis 26(4):477-480 PMID: 37640982
- 3. Kostourou V et al.. 2014. Non-collagenous ECM proteins in blood vessel morphogenesis and cancer.. Biochim Biophys Acta 1840(8):2403-13 PMID: 24576673
- 4. Kusumbe AP et al.. 2014. Coupling of angiogenesis and osteogenesis by a specific vessel subtype in bone.. Nature 507(7492):323-328 PMID: 24646994
- 5. Senger DR et al.. 2011. Angiogenesis.. Cold Spring Harb Perspect Biol 3(8):a005090 PMID: 21807843
- 6. Herbert SP et al.. 2011. Molecular control of endothelial cell behaviour during blood vessel morphogenesis.. Nat Rev Mol Cell Biol 12(9):551-64 PMID: 21860391
- 7. Iruela-Arispe ML et al.. 2013. Tubulogenesis.. Development 140(14):2851-5 PMID: 23821032
- 8. Ramasamy SK et al.. 2014. Endothelial Notch activity promotes angiogenesis and osteogenesis in bone.. Nature 507(7492):376-380 PMID: 24647000
